Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Inclusion Criteria: * Patient receiving FOLFIRINOX chemotherapy * Southwest Oncology Group (SWOG) Performance status 0 or 1 * Ability of patient or guardian to understand and to provide voluntary written informed consent Exclusion Criteria: * Patient with current illness requiring chronic systemic steroids use or requiring chronic use of anti emetics * Patients with gastrointestinal (GI) obstruction or active peptic ulcer disease who cannot take oral medication * Known hypersensitivity to any component of the study regimen * Patients taking any of the following medications: Oral contraceptives (except for the administration of stopping menses), tolbutamide, phenytoin, midazolam, ketoconazole, rifampin, paroxetine, and Diltiazem * Pregnant or nursing women * Patients using illegal drugs